Robert Cavorsi
Corporate Officer/Principal chez ORGANOGENESIS HOLDINGS INC.
Fortune : 131 237 $ au 30/04/2024
Profil
Robert Cavorsi is currently the Vice President-Strategy at Organogenesis Holdings, Inc. He previously worked as the Neurology Director-Sales Operations at Sumitomo Pharma America, Inc. from 2015 to 2016.
He obtained his undergraduate degree from The Pennsylvania State University.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
19/04/2024 | 57 434 ( 0,04% ) | 131 237 $ | 30/04/2024 |
Postes actifs de Robert Cavorsi
Sociétés | Poste | Début |
---|---|---|
ORGANOGENESIS HOLDINGS INC. | Corporate Officer/Principal | 01/01/2021 |
Anciens postes connus de Robert Cavorsi
Sociétés | Poste | Fin |
---|---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Sales & Marketing | 01/01/2016 |
Formation de Robert Cavorsi
The Pennsylvania State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
ORGANOGENESIS HOLDINGS INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Health Technology |